<DOC>
	<DOCNO>NCT02349451</DOCNO>
	<brief_summary>This study Phase 2 randomize , double-blind , double-dummy , active- placebo-controlled , parallel-group study design assess safety , tolerability , efficacy , pharmacokinetics immunogenicity multiple dose ABT-122 subject active psoriatic arthritis ( PsA ) inadequately respond methotrexate ( MTX ) treatment .</brief_summary>
	<brief_title>A Phase 2 Study Investigate Safety , Tolerability Efficacy ABT-122 Subjects With Active Psoriatic Arthritis Who Have Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>PsA diagnosis least 3 month duration prior date first screen ClASsification Psoriatic ARthritis ( CASPAR ) confirm diagnosis Screening . Have active psoriasis define least 1 psoriasis lesion &gt; = 2 cm diameter area axilla groin . Have active arthritis define minimum disease activity criterion : 1 . &gt; = 3 Swollen joint ( base 66 joint count ) Screening 2 . &gt; = 3 Tender joint ( base 68 joint count ) Screening On stable dose methotrexate ( MTX ) define : 1 . Oral parenteral treatment &gt; = 3 month , 2 . On stable dose unchanged mode application least 4 week prior baseline 3 . Stable MTX dose &gt; = 10 mg/week &lt; = upper limit applicable approve local label . 4 . Subject also stable dos nonsteroidal antiinflammatory drug ( NSAIDs ) , sulfasalazine and/or hydroxychloroquine long also methotrexate . Prior exposure tumor necrosis factor ( TNF ) inhibitor include : Up 30 % ( approximately 66 subject ) prior exposure TNF inhibitor may enrol TNF inhibitor discontinue due lack efficacy safety concern . Subjects must wash least 5 halflives drug prior Baseline visit . 1 . Subjects prior adalimumab may enrol study . 2 . Prior exposure nonTNF inhibitor biological diseasemodifying antirheumatic drug ( DMARDs ) permit subject wash least 5 halflives drug prior baseline visit . Current treatment traditional oral DMARDs , include conventional synthetic DMARDs ( csDMARDs ) , ( except concomitant treatment sulfasalazine and/or hydroxychloroquine addition MTX ) . Oral DMARDs must wash least 5 halflives drug apart MTX prior Baseline visit . . Subject could expose prior Janus kinase ( JAK ) inhibitor long therapy least 5 halflives . Stable prescribed dose oral prednisone prednisone equivalent &gt; 10 mg/day within 30 day Baseline visit . Intraarticular parenteral administration corticosteroid precede 4 week Baseline visit . Inhaled corticosteroid stable medical condition allow . Laboratory value follow Screening Visit : 1 . Confirmed hemoglobin &lt; 9 g/dL male &lt; 8.5 g/dL female , 2 . Absolute neutrophil count ( ANC ) &lt; 1500 mm3 , ( &lt; 1200 cells/ÂµL subject African descent black ) , 3 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 1.5 x upper limit normal ( ULN ) bilirubin &gt; = 3 mg/dL , 4 . Serum creatinine &gt; 1.5 x ULN , 5 . Platelets &lt; 100,000 cells/ [ mm3 ] ( 109/L ) , 6 . Clinically significant abnormal screen laboratory result evaluate Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Safety</keyword>
</DOC>